Comparing Open Surgery and Keyhole Surgery With a Stapler for Early Cervical Cancer
Compares two ways of removing the uterus in women with early cervical cancer.
Plain-language title generated from the registry record
Registry title: Minimally Invasive Radical Hysterectomy Using Endoscopic Stapler in Stage IB2 or IIA1 Cervical Cancer
Key facts
- Where
- Seoul, South KoreaSee the site
Where in South Korea
- Seoul National University College of MedicineSeoul, South KoreaNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Seoul National University Hospital
- Trial code
- NCT07256977
- Record updated
- 2 December 2025
- Original description
This study is a multicenter, open-label, non-inferiority, randomized controlled, investigator-initiated clinical trial comparing the efficacy and safety of open radical hysterectomy versus minimally invasive radical hysterectomy using an endoscopic stapler as surgical treatments for early cervical cancer.Read full original descriptionShow less
A Multicenter Non-inferiority Randomized Controlled Trial on Minimally Invasive Radical Hysterectomy Using an Endoscopic Stapler to Prevent Tumor Spillage in Stage IB2-IIA1 Cervical Cancer
This study is a multicenter, open-label, non-inferiority, randomized controlled, investigator-initiated clinical trial comparing the efficacy and safety of open radical hysterectomy versus minimally invasive radical hysterectomy using an endoscopic stapler as surgical treatments for early cervical cancer.
Inclusion Criteria:; 2018 FIGO stage IB2 or IIA1 cervical cancer (tumor maximum diameter ≥2 cm and <4 cm); Histologically confirmed squamous cell carcinoma, adenocarcinoma, or adenosquamous carcinoma; Planned for Type B or C radical hysterectomy; With adequate bone marrow, renal, and hepatic function; WBC >3.0 × 10⁹ cells/L; Platelets >100 × 10⁹ cells/L; Creatinine <180 μmol/L; Bilirubin <1.5 × normal range; AST, ALT < 3 × normal range; Eastern Cooperative Oncology Group (ECOG) performance status 0-2; Previous history of other invasive malignancies with no evidence of recurrence for at least 5 years; Signed and approved consent form; Exclusion Criteria:; Histological types other than squamous cell carcinoma, adenocarcinoma, or adenosquamous carcinoma; Tumor size less than 2 cm classified as 2018 FIGO stage IA1, IA2, or IB1 disease; The following are observed on preoperative CT or MRI; Tumor size ≥4 cm; Lymph node metastasis (short axis ≥15 mm); Paracervical invasion; Bladder or rectal invasion; Distant metastasis; Prior pelvic or abdominal radiotherapy; Prior neoadjuvant chemotherapy before surgery; Unsuitable for surgery due to severe systemic disease at the investigator's discretion; Difficult to consider intraoperative lymphatic mapping due to; Allergy to triphenylmethane compounds; History of prior retroperitoneal surgery; History of prior pelvic radiotherapy; Cases where cold knife or loop electrosurgical excision procedure (LEEP) was performed within 4 weeks prior to study participation; Allergy to triphenylmethane compounds.